Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biohaven Ltd. stock logo
BHVN
Biohaven
$13.90
+0.8%
$16.42
$13.75
$55.70
$1.41B0.911.29 million shs1.11 million shs
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
$6.88
+3.9%
$6.26
$4.02
$15.10
$359.32M2.091.71 million shs929,673 shs
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
$6.22
+2.8%
$6.12
$5.51
$12.65
$1.86B0.513.18 million shs4.19 million shs
uniQure N.V. stock logo
QURE
uniQure
$14.44
+0.9%
$14.55
$4.45
$19.18
$783.85M0.081.95 million shs704,160 shs
Zogenix, Inc. stock logo
ZGNX
Zogenix
$26.68
$26.52
$11.03
$26.90
$1.50B0.893.76 million shs94 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biohaven Ltd. stock logo
BHVN
Biohaven
+0.65%-0.29%-18.19%-25.47%-59.65%
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
+3.77%+4.40%+3.61%+47.01%-15.48%
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
+2.81%+6.51%+0.97%-9.72%-38.84%
uniQure N.V. stock logo
QURE
uniQure
+0.91%+3.22%-16.39%+57.64%+282.01%
Zogenix, Inc. stock logo
ZGNX
Zogenix
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biohaven Ltd. stock logo
BHVN
Biohaven
3.1848 of 5 stars
4.51.00.00.01.82.50.6
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
4.2966 of 5 stars
3.51.00.04.62.12.51.3
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
3.6815 of 5 stars
3.41.00.04.30.60.01.9
uniQure N.V. stock logo
QURE
uniQure
2.1256 of 5 stars
3.51.00.00.01.52.50.6
Zogenix, Inc. stock logo
ZGNX
Zogenix
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biohaven Ltd. stock logo
BHVN
Biohaven
3.07
Buy$58.46320.59% Upside
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
3.00
Buy$14.33108.33% Upside
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
2.70
Moderate Buy$16.22160.81% Upside
uniQure N.V. stock logo
QURE
uniQure
2.91
Moderate Buy$37.82161.90% Upside
Zogenix, Inc. stock logo
ZGNX
Zogenix
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest BHVN, FOLD, EBS, ZGNX, and QURE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$68.00 ➝ $55.00
5/30/2025
uniQure N.V. stock logo
QURE
uniQure
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$38.00
5/29/2025
uniQure N.V. stock logo
QURE
uniQure
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$70.00
5/19/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Sector Perform$54.00 ➝ $21.00
5/19/2025
uniQure N.V. stock logo
QURE
uniQure
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/13/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/13/2025
Biohaven Ltd. stock logo
BHVN
Biohaven
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$61.00 ➝ $54.00
5/12/2025
uniQure N.V. stock logo
QURE
uniQure
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
5/12/2025
uniQure N.V. stock logo
QURE
uniQure
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
5/6/2025
uniQure N.V. stock logo
QURE
uniQure
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
5/2/2025
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$21.00 ➝ $22.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biohaven Ltd. stock logo
BHVN
Biohaven
N/AN/AN/AN/A$4.19 per shareN/A
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
$1.04B0.36$1.99 per share3.45$8.91 per share0.77
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
$528.29M3.63N/AN/A$0.65 per share9.57
uniQure N.V. stock logo
QURE
uniQure
$20.20M39.15N/AN/A($0.14) per share-103.14
Zogenix, Inc. stock logo
ZGNX
Zogenix
$81.69M18.36N/AN/A$6.64 per share4.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biohaven Ltd. stock logo
BHVN
Biohaven
-$846.42M-$9.36N/AN/AN/AN/A-257.07%-164.01%8/5/2025 (Estimated)
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
-$190.60M-$2.71N/A3.32N/A-13.63%-0.52%-0.17%8/5/2025 (Estimated)
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
-$56.11M-$0.09N/A14.47N/A-5.41%4.67%1.05%8/14/2025 (Estimated)
uniQure N.V. stock logo
QURE
uniQure
-$239.56M-$4.39N/AN/AN/A-1,077.05%-483.87%-34.28%8/7/2025 (Estimated)
Zogenix, Inc. stock logo
ZGNX
Zogenix
-$209.38M-$4.07N/AN/AN/A-278.38%-91.20%-43.60%N/A

Latest BHVN, FOLD, EBS, ZGNX, and QURE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
$0.21N/AN/AN/A$148.55 millionN/A
5/12/2025Q1 2025
Biohaven Ltd. stock logo
BHVN
Biohaven
-$1.67-$2.17-$0.50-$2.17$1.25 millionN/A
5/9/2025Q1 2025
uniQure N.V. stock logo
QURE
uniQure
-$1.07-$0.82+$0.25-$0.82$5.93 million$1.57 million
5/7/2025Q1 2025
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
$0.49$0.71+$0.22$1.19$218.50 million$222.20 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biohaven Ltd. stock logo
BHVN
Biohaven
N/AN/AN/AN/AN/A
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
N/AN/AN/AN/AN/A
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
N/AN/AN/AN/AN/A
uniQure N.V. stock logo
QURE
uniQure
N/AN/AN/AN/AN/A
Zogenix, Inc. stock logo
ZGNX
Zogenix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biohaven Ltd. stock logo
BHVN
Biohaven
N/A
2.33
2.33
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
1.20
6.32
3.51
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
2.02
3.34
2.47
uniQure N.V. stock logo
QURE
uniQure
1.53
11.99
11.99
Zogenix, Inc. stock logo
ZGNX
Zogenix
0.88
3.63
4.74

Institutional Ownership

CompanyInstitutional Ownership
Biohaven Ltd. stock logo
BHVN
Biohaven
88.78%
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
78.40%
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
N/A
uniQure N.V. stock logo
QURE
uniQure
78.83%
Zogenix, Inc. stock logo
ZGNX
Zogenix
N/A

Insider Ownership

CompanyInsider Ownership
Biohaven Ltd. stock logo
BHVN
Biohaven
14.60%
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
3.20%
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
2.20%
uniQure N.V. stock logo
QURE
uniQure
4.79%
Zogenix, Inc. stock logo
ZGNX
Zogenix
4.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biohaven Ltd. stock logo
BHVN
Biohaven
239102.11 million87.21 millionOptionable
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
2,42054.28 million52.54 millionOptionable
Amicus Therapeutics, Inc. stock logo
FOLD
Amicus Therapeutics
480307.93 million301.16 millionOptionable
uniQure N.V. stock logo
QURE
uniQure
50054.78 million52.15 millionOptionable
Zogenix, Inc. stock logo
ZGNX
Zogenix
21856.23 million53.92 millionOptionable

Recent News About These Companies

Hwasung Industrial Co Ltd 002460
Orally Inhaled Dihydroergotamine
MRI in Headache
Kratom: What We Know
Alcon (NYSE: ALC)
Longeveron Inc Ordinary Shares - Class A

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biohaven stock logo

Biohaven NYSE:BHVN

$13.90 +0.11 (+0.80%)
Closing price 07/8/2025 03:59 PM Eastern
Extended Trading
$14.17 +0.27 (+1.94%)
As of 05:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Emergent Biosolutions stock logo

Emergent Biosolutions NYSE:EBS

$6.88 +0.26 (+3.93%)
Closing price 07/8/2025 03:59 PM Eastern
Extended Trading
$6.99 +0.11 (+1.58%)
As of 05:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Amicus Therapeutics stock logo

Amicus Therapeutics NASDAQ:FOLD

$6.22 +0.17 (+2.81%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$6.22 +0.00 (+0.08%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

uniQure stock logo

uniQure NASDAQ:QURE

$14.44 +0.13 (+0.91%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$14.60 +0.16 (+1.11%)
As of 06:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Zogenix stock logo

Zogenix NASDAQ:ZGNX

Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.